Product Information
COMBIVENT RESPIMAT 20-100 MCG is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $124.1581 per GM under NDC 00597002402. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 7, 2011.
Strength
100; 20 ug/1; ug/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597002402
Classification
Brand
Dosage Form
SPRAY, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
ALBUTEROL SULFATE; IPRATROPIUM BROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA021747FDA Approved
10/7/2011
On Market Since
7/1/2012
Pharmacological Classes
Price Statistics
The NADAC for COMBIVENT RESPIMAT 20-100 MCG has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 93.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $124.1581 per GM |
|---|---|
| All-time high | $124.2865 (May 13, 2026) |
| All-time low | $63.8516 (May 21, 2014) |
| 52-week high | $124.2865 |
| 52-week low | $120.6544 |
| Median price | $102.2117 |
| Average price | $97.2509 |
| Largest weekly change | +8.0% (Apr 13, 2016) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ipratropium bromide and albuterol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ipratropium bromide and albuterol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COMBIVENT RESPIMAT 20-100 MCG?
The current National Average Drug Acquisition Cost (NADAC) for COMBIVENT RESPIMAT 20-100 MCG, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $124.1581 per GM (NDC 00597002402), effective Sep 30, 2026.
How has the price of COMBIVENT RESPIMAT 20-100 MCG changed over time?
Over the history we have for it, the NADAC for COMBIVENT RESPIMAT 20-100 MCG has risen 93.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for COMBIVENT RESPIMAT 20-100 MCG?
Since Nov 28, 2013, the NADAC for COMBIVENT RESPIMAT 20-100 MCG has ranged from a low of $63.8516 (May 21, 2014) to a high of $124.2865 (May 13, 2026), with a median of $102.2117 per GM.
Are there cheaper alternatives to COMBIVENT RESPIMAT 20-100 MCG?
No other NADAC-published product currently shares the active ingredient and strength of COMBIVENT RESPIMAT 20-100 MCG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures COMBIVENT RESPIMAT 20-100 MCG?
COMBIVENT RESPIMAT 20-100 MCG (NDC 00597002402) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.